Luminal B breast cancers are HR+/HER2+ and account for ~10 percent, while HER2-enriched (HER2+) breast cancers account for about ~15–20% and triple negative breast cancer (HR-/HER2-) (TNBC) accounts for ~12% [2]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.